NASDAQ: INVAInnoviva Inc Stock Ownership - Who owns Innoviva?
Insider buying vs selling
Have Innoviva Inc insiders been buying or selling?
Buy
Sell
| Name | Role | Date | Shares | Price | Value |
|---|---|---|---|---|---|
| Stephen Basso | Chief Financial Officer | 2025-11-20 | 237 | $21.16 | $5.01kSell |
| Marianne Zhen | Chief Accounting Officer | 2025-11-20 | 992 | $21.16 | $20.99kSell |
| Pavel Raifeld | 10% Owner | 2025-11-03 | 110,436 | $18.11 | $2.00MBuy |
| Stephen Basso | Chief Financial Officer | 2025-11-03 | 27,609 | $18.11 | $500.00kBuy |
| Marianne Zhen | Chief Accounting Officer | 2025-08-20 | 991 | $19.95 | $19.77kSell |
| Stephen Basso | Chief Financial Officer | 2025-08-20 | 237 | $19.95 | $4.73kSell |
| Stephen Basso | Chief Financial Officer | 2025-05-20 | 237 | $18.78 | $4.45kSell |
| Marianne Zhen | Chief Accounting Officer | 2025-05-20 | 992 | $18.78 | $18.63kSell |
| Pavel Raifeld | 10% Owner | 2025-03-14 | 37,377 | $17.39 | $649.99kBuy |
| Alexander J. Denner | 10% Owner | 2025-03-06 | 1,196,746 | $17.52 | $20.96MSell |
INVA insiders have sold more... subscribe to Premium to read more.
Net Insider Buy/Sell (L12M) Ownership
Be the first to know when INVA insiders and whales buy or sell their stock.
INVA Shareholders
What type of owners hold Innoviva Inc stock?
Institutional
Insider
Retail
| Name | Hold | Shares | Value | Type |
|---|---|---|---|---|
| Glaxosmithkline PLC | 42.81% | 32,005,260 | $640.11M | Insider |
| Blackrock Inc | 12.62% | 9,436,812 | $188.74M | Institution |
| Vanguard Group Inc | 9.49% | 7,097,346 | $141.95M | Institution |
| Alexander J. Denner | 7.57% | 5,658,705 | $113.17M | Insider |
| Renaissance Technologies LLC | 6.13% | 4,586,932 | $91.74M | Institution |
| Dimensional Fund Advisors LP | 5.79% | 4,330,353 | $86.61M | Institution |
| Jeffrey M. Drazan | 3.87% | 2,893,921 | $57.88M | Insider |
| Sarissa Capital Management LP | 3.77% | 2,816,022 | $56.32M | Institution |
| State Street Corp | 3.42% | 2,556,972 | $51.14M | Institution |
| Franklin Resources Inc | 3.34% | 2,497,781 | $49.96M | Institution |
INVA vs Biotech Stocks
Innoviva Stock Ownership FAQ
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.